Rich66
05-03-2012, 08:16 AM
J Pathol. (http://www.ncbi.nlm.nih.gov/pubmed?term=The%20interplay%20of%20HER2%2FHER3%2FP I3K%20and%20EGFR%2FHER2%2FPLC-1%20signalling%20in%20breast%20cancer%20cell%20mig ration%20and%20dissemination#) 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Epub 2012 Mar 21.
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Balz%20LM%22%5BAuthor%5D), Bartkowiak K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bartkowiak%20K%22%5BAuthor%5D), Andreas A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Andreas%20A%22%5BAuthor%5D), Pantel K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pantel%20K%22%5BAuthor%5D), Niggemann B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Niggemann%20B%22%5BAuthor%5D), Zänker KS (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Z%C3%A4nker%20KS%22%5BAuthor%5D), Brandt BH (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brandt%20BH%22%5BAuthor%5D), Dittmar T (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dittmar%20T%22%5BAuthor%5D).
LINK (http://onlinelibrary.wiley.com/doi/10.1002/path.3991/abstract;jsessionid=AB12FA0C80091BC501C8D3B135A5AF F4.d04t01)
Source
Institute of Immunology, Witten/Herdecke University, Germany.
Abstract
HER2 signalling by heterodimerisation with EGFR and HER3 in breast cancer is associated with worst outcome of the afflicted patients, which is attributed not only to the aggressiveness of such tumours but also to therapy resistance. Thus, in the present study we investigated the role of EGFR, HER2 and HER3 lateral signalling in cell migration by applying the MDA-MB-468-HER2 (MDA-HER2) breast cancer cell line, representing a valid model system. Knockdown of HER3 expression by siRNA resulted in decreased phosphorylated AKT (pAKT) levels, abrogated epidermal growth factor (EGF)-mediated PLC-γ1 activation and a diminished EGF-induced migratory activity, depicting the interplay of EGF receptor (EGFR)/HER2/PLC-γ1 and HER2/HER3/PI3K signalling in mediating the migration of EGFR/HER2/HER3-expressing breast cancer cells. Since therapy failure usually arises from metastatic cells, we further investigated whether HER3 signalling was active in established breast cancer disseminated tumour cell (DTC) lines as well as in primary DTCs derived from breast cancer patients. EGF treatment of DTC lines resulted solely in increased pAKT S473 levels, whereas in MDA-HER2 cells both pAKT S473 and pAKT T308 levels were increased upon EGF stimulation. Moreover, despite active HER3 molecules, as indicated by pTyr1222 staining, about 90% of analysed breast cancer patient DTCs exhibited very low or even no detectable pAKT S473 levels, suggesting that these cells might have fallen into dormancy. In summary, our data indicate the important role in EGFR, HER2 and HER3 lateral signalling in breast cancer cell migration. Moreover, our data further show that primary tumour cells and DTCs can vary in their HER activation status, which is important to know in the context of cancer therapy. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
<DL class=rprtid><DT>PMID: <DD>22262199 <DD>[PubMed - in process] <DD></DD></DL>
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Balz%20LM%22%5BAuthor%5D), Bartkowiak K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bartkowiak%20K%22%5BAuthor%5D), Andreas A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Andreas%20A%22%5BAuthor%5D), Pantel K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pantel%20K%22%5BAuthor%5D), Niggemann B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Niggemann%20B%22%5BAuthor%5D), Zänker KS (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Z%C3%A4nker%20KS%22%5BAuthor%5D), Brandt BH (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brandt%20BH%22%5BAuthor%5D), Dittmar T (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dittmar%20T%22%5BAuthor%5D).
LINK (http://onlinelibrary.wiley.com/doi/10.1002/path.3991/abstract;jsessionid=AB12FA0C80091BC501C8D3B135A5AF F4.d04t01)
Source
Institute of Immunology, Witten/Herdecke University, Germany.
Abstract
HER2 signalling by heterodimerisation with EGFR and HER3 in breast cancer is associated with worst outcome of the afflicted patients, which is attributed not only to the aggressiveness of such tumours but also to therapy resistance. Thus, in the present study we investigated the role of EGFR, HER2 and HER3 lateral signalling in cell migration by applying the MDA-MB-468-HER2 (MDA-HER2) breast cancer cell line, representing a valid model system. Knockdown of HER3 expression by siRNA resulted in decreased phosphorylated AKT (pAKT) levels, abrogated epidermal growth factor (EGF)-mediated PLC-γ1 activation and a diminished EGF-induced migratory activity, depicting the interplay of EGF receptor (EGFR)/HER2/PLC-γ1 and HER2/HER3/PI3K signalling in mediating the migration of EGFR/HER2/HER3-expressing breast cancer cells. Since therapy failure usually arises from metastatic cells, we further investigated whether HER3 signalling was active in established breast cancer disseminated tumour cell (DTC) lines as well as in primary DTCs derived from breast cancer patients. EGF treatment of DTC lines resulted solely in increased pAKT S473 levels, whereas in MDA-HER2 cells both pAKT S473 and pAKT T308 levels were increased upon EGF stimulation. Moreover, despite active HER3 molecules, as indicated by pTyr1222 staining, about 90% of analysed breast cancer patient DTCs exhibited very low or even no detectable pAKT S473 levels, suggesting that these cells might have fallen into dormancy. In summary, our data indicate the important role in EGFR, HER2 and HER3 lateral signalling in breast cancer cell migration. Moreover, our data further show that primary tumour cells and DTCs can vary in their HER activation status, which is important to know in the context of cancer therapy. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
<DL class=rprtid><DT>PMID: <DD>22262199 <DD>[PubMed - in process] <DD></DD></DL>